Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed ...

Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with ...

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

Trump's drug pricing EO includes wins on pill penalty reform, faster approvals, and PBM rules, but adds scrutiny on pricing ...

Jacob Elkins has left Sarepta to take the CMO job at AIRNA, the RNA editing shop that disclosed a $155 million Series ...

UnitedHealth Group reported disappointing first-quarter earnings and cut its financial guidance, hit by high costs in its ...

The London biotech Charm Therapeutics is looking for a new top executive to replace founding CEO Laksh Aithani, Endpoints ...

Roche is stopping patients on the low dose of its experimental Huntington’s drug tominersen, and will be transitioning them ...